Compare Abbott Laboratories (ABT) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Opendoor Technologies Inc — how do they compare? Abbott Laboratories trades at $95.18 (market cap $166.94B), while Opendoor Technologies Inc trades at $4.76 (market cap $4.62B). The key difference: Abbott Laboratories is far larger — about 36.1× Opendoor Technologies Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals.
| ABT | OPEN | |
|---|---|---|
Market Cap | $166.94B | $4.62B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $10.52 |
52-Week Low | $82.57 | $0.73 |
Enterprise Value | $193.69B | $4.96B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Opendoor Technologies (OPEN) trades at $4.79, down 2.24% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net income margin of -35.25%. Recent news highlights a new CEO, a shift to the Opendoor 2.0 model, and the closure of India operations to focus on AI-driven efficiencies.
The outlook remains challenging with persistent losses and a highly leveraged balance sheet, though cost discipline and AI integration offer potential for margin improvement. Key risks include housing market volatility and high debt levels. Analyst consensus is cautious with 65.39% hold ratings, reflecting uncertainty around the path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
